Relationships between SF-36 health profile and bone mineral density: the Hertfordshire Cohort Study

Dennison, Elaine; Syddall, Holly; Statham, Charles N.; Sayer, Avan Aihie; Cooper, Cyrus

doi:10.1007/s00198-006-0151-9

Cited by 28 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies that compared women with and without BMD-measured osteoporosis found no significant differences in these outcomes [42,43]. However, these studies compared normal, osteopenic and osteoporotic women, and while scores for osteoporotic women did seem worse, differences between normal and osteopenic women were minimal.…”

Section: Construct Validity Of Self-reported Diagnosismentioning

confidence: 95%

Validity of self-reported osteoporosis in mid-age and older women

et al. 2012

View full text Add to dashboard Cite

Conflict of Interest: None declared Mini-abstract:The validity of self-reported osteoporosis is often questioned, but validation studies are lacking. We validated self-reported prevalence and incidence of osteoporosis against selfreported and administrative data on medications. The concurrent validity was moderate to good for self-reported prevalent osteoporosis, but only poor to moderate for self-reported incident osteoporosis in mid-age and older women, respectively. Construct validity was acceptable for self-reported prevalent but not for incident osteoporosis. 2 Abstract PurposeThe validity of self-reported osteoporosis is often questioned, but validation studies are lacking. The aim was to examine the validity of self-reported prevalence and incidence of osteoporosis against self-reported and administrative data on medications. MethodsData were from mid-age (56-61 years in 2007) and older (79-84 years in 2005) participants in the Australian Longitudinal Study on Women's Health. Self-reported diagnosis was compared with medication information from (1) self-report (n mid =10,509 and n old =7,072), and (2) pharmaceutical prescription reimbursement claims (n mid =6,632 and n old =4,668). Concurrent validity of self-report was examined by calculating agreement, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).Construct validity was tested by examining associations of self-reported diagnosis with osteoporosis-related characteristics (fracture, weight, bodily pain, back pain, and physical functioning). ResultsAgreement, sensitivity and PPV of self-reported prevalent diagnosis were higher when compared with medication claims (mid-age women: kappa=0.51, 95%CI=0.46-0.56; older women: kappa=0.65, 95%CI=0.63-0.68) than with self-reported medication (midage women: kappa=0.41, 95%CI=0.37-0.45; older women: kappa=0.57, 95%CI=0.55-0.59).Sensitivity, PPV and agreement were lower for self-reported incident diagnosis (mid-age women: kappa=0.39, 95%CI=0.32-0.47; older women: kappa=0.55, 95%CI=0.51-0.61).Statistically significant associations between self-reported diagnosis and at least four of five characteristics were found for prevalent diagnosis in both age groups and for incident diagnosis in older women. ConclusionsThe concurrent validity was moderate to good for self-reported prevalent osteoporosis, but only poor to moderate for self-reported incident osteoporosis in mid-age 3 and older women, respectively. Construct validity was acceptable for self-reported prevalent but not for incident osteoporosis.4

show abstract

Section: Construct Validity Of Self-reported Diagnosismentioning

confidence: 95%

Validity of self-reported osteoporosis in mid-age and older women

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Poorer functioning (assessed by SF-36 questionnaire) is associated with lower total femoral BMD in middle-aged men (but less so in women) adjusting for known co-morbidities[35].…”

mentioning

confidence: 99%

An updated systematic review of Health State Utility Values for osteoporosis related conditions

et al. 2009

View full text Add to dashboard Cite

show abstract

“…This questionnaire assesses eight domains: PF (physical function), RP (role-physical), BP (bodily pain), GH (general health), VT (vitality), SF (social function), RE (role-emotional), MH (mental health), and two summary scores: PCS (physical component summary) and MCS (mental component summary) [18]. PCS is the average of the first four domains, and MCS is the average of the last four domains.…”

Section: Hrql: Sf-36mentioning

confidence: 99%

“…Each domain is scored and interpreted separately, rather than obtaining a total score, so each question was analysed individually and grouped according to the domains that they represent. All domain scores range from 0 to 100, with higher scores indicating better HRQL [18].…”

Section: Hrql: Sf-36mentioning

confidence: 99%

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Huang¹,

Lin²,

Zhu³

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

 Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosisKwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia AbstractIntroduction: Osteoporosis is characterised by decreased bone mass and weakened bones, with an increased risk of fractures. Osteoporotic fracture, the most serious complication of osteoporosis, is related not only to lower bone mineral density (BMD), but also falls. Osteoporosis and fractures are associated with a decreased health-related quality of life (HRQL). Zoledronic acid (ZOL) is an intravenous once-yearly bisphosphonate that has been shown to be effective and safe in improving BMD and reducing fracture risk in controlled clinical trials. Material and methods:In this self-controlled, prospective trial, 220 postmenopausal women with osteoporosis (mean age 67 years) received a single infusion of ZOL 5 mg at baseline and month 12. BMD, HRQL and Fall Index (FI) were measured at baseline, and months 12 and 24 (before each use of ZOL). The main outcome measures were the changes in lumbar spine and hip BMD and the changes in HRQL, the Short Form-36 questionnaire (SF-36). Additional comparisons were based on the FI. LSD multiple comparisons were used in the comparisons of BMD, SF-36 domain scores and FI. Results: The patients had significantly higher L1-4, total hip, femoral neck and trochanter BMD (P < 0.05) with improved HRQL (P < 0.05) over two years of treatment of once-yearly ZOL 5mg. FI was reduced (P < 0.05) with oral daily elemental calcium and vitamin D in the treatment course. Conclusions: ZOL improves BMD and HRQL, especially in the physical aspects, over two years of treatment in women with postmenopausal osteoporosis, and can help improve balance ability. (Endokrynol Pol 2014; 65 (2): 96-104)

show abstract

Relationships between SF-36 health profile and bone mineral density: the Hertfordshire Cohort Study

Cited by 28 publications

References 17 publications

Validity of self-reported osteoporosis in mid-age and older women

Validity of self-reported osteoporosis in mid-age and older women

An updated systematic review of Health State Utility Values for osteoporosis related conditions

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Contact Info

Product

Resources

About